BACKGROUND: Mild cognitive impairment (MCI) is an etiologically unclear disorder. Cerebrospinal fluid (CSF) biomarkers are potentially useful for the differentiation between various MCI etiologies. AIM: The aim of the study was to assess whether baseline CSF hyperphosphorylated tau (P-tau), total tau (T-tau), amyloid beta 1-42 (Abeta(42)) and neurofilament light (NF-L) in patients with MCI could predict subcortical vascular dementia (SVD) and Alzheimer's disease (AD) at follow-up. METHODS: Biomarker levels were assessed by Luminex xMAP technology and ELISA. RESULTS: Increased baseline concentrations of NF-L significantly separated MCI-SVD from stable MCI. The MCI-SVD patients were inseparable from stable MCI but separable from patients developing AD (MCI-AD) on the basis of Abeta(42,) T-tau and P-tau(181) levels. CONCLUSION: A combination of the biomarkers Abeta(42), T-tau, P-tau(181) and NF-L has the potential to improve the clinical separation of MCI-SVD patients from stable MCI and MCI-AD patients. 2009 S. Karger AG, Basel.
BACKGROUND: Mild cognitive impairment (MCI) is an etiologically unclear disorder. Cerebrospinal fluid (CSF) biomarkers are potentially useful for the differentiation between various MCI etiologies. AIM: The aim of the study was to assess whether baseline CSF hyperphosphorylated tau (P-tau), total tau (T-tau), amyloid beta 1-42 (Abeta(42)) and neurofilament light (NF-L) in patients with MCI could predict subcortical vascular dementia (SVD) and Alzheimer's disease (AD) at follow-up. METHODS: Biomarker levels were assessed by Luminex xMAP technology and ELISA. RESULTS: Increased baseline concentrations of NF-L significantly separated MCI-SVD from stable MCI. The MCI-SVDpatients were inseparable from stable MCI but separable from patients developing AD (MCI-AD) on the basis of Abeta(42,) T-tau and P-tau(181) levels. CONCLUSION: A combination of the biomarkers Abeta(42), T-tau, P-tau(181) and NF-L has the potential to improve the clinical separation of MCI-SVDpatients from stable MCI and MCI-ADpatients. 2009 S. Karger AG, Basel.
Authors: Davide Bruno; Nunzio Pomara; Jay Nierenberg; James C Ritchie; Michael W Lutz; Henrik Zetterberg; Kaj Blennow Journal: Exp Gerontol Date: 2011-10-01 Impact factor: 4.032
Authors: A Vilar-Bergua; I Riba-Llena; C Nafría; A Bustamante; V Llombart; P Delgado; J Montaner Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Joel Jakobsson; Maria Bjerke; Carl Johan Ekman; Carl Sellgren; Anette G M Johansson; Henrik Zetterberg; Kaj Blennow; Mikael Landén Journal: Neuropsychopharmacology Date: 2014-04-03 Impact factor: 7.853
Authors: Clara Hjalmarsson; Maria Bjerke; Björn Andersson; Kaj Blennow; Henrik Zetterberg; N David Aberg; Bob Olsson; Carl Eckerström; Lena Bokemark; Anders Wallin Journal: J Cent Nerv Syst Dis Date: 2014-05-19
Authors: Maria Bjerke; Michael Jonsson; Arto Nordlund; Carl Eckerström; Kaj Blennow; Henrik Zetterberg; Leonardo Pantoni; Domenico Inzitari; Reinhold Schmidt; Anders Wallin Journal: Dement Geriatr Cogn Dis Extra Date: 2014-10-21
Authors: Anders Wallin; Arto Nordlund; Michael Jonsson; Kaj Blennow; Henrik Zetterberg; Annika Öhrfelt; Jacob Stålhammar; Marie Eckerström; Mårten Carlsson; Erik Olsson; Mattias Göthlin; Johan Svensson; Sindre Rolstad; Carl Eckerström; Maria Bjerke Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Yemisi Takwoingi; Leon Flicker; Sam E Mason; Rupert McShane Journal: Cochrane Database Syst Rev Date: 2014-06-10